Search results
Results from the WOW.Com Content Network
Regigigas has an in-battle ability known as Slow Start, meant to reflect its long period of dormancy in-universe. Slow Start halves Regigigas's attack power and speed for five in-battle turns. [6] Pokémon Sword and Shield's downloadable content expansion pass The Crown Tundra introduced two more members to the group, Regieleki and Regidrago.
In clinical trials supported by Novo Nordisk, gallstones were reported in 1.5 percent of participants taking a 0.5 mg dose of semaglutide and 0.4 percent of those taking the 1 mg dose. No cases of ...
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. [8] [9] It is generally less preferred than metformin and sulfonylureas as an initial treatment.
Extended-release (or slow-release) formulations of morphine are those whose effect last substantially longer than bare morphine, availing for, e.g., one administration per day. Conversion between extended-release and immediate-release (or "regular") morphine is easier than conversion to or from an equianalgesic dose of another opioid with ...
Lemborexant is used in the treatment of insomnia in adults. [3]A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found that lemborexant had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.36 (95% CI Tooltip confidence interval 0.08 to 0.63) and at 3 months of 0.41 (95% ...
Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. [2] [6] It is used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. [7]
After 24 weeks, the reduction from baseline for HbA1c was 0.81% for gemigliptin 25 mg twice a day (bid) and 0.77% for gemigliptin 50 mg qd, and the differences in the least square mean changes from baseline between groups (each group of gemigliptin-sitagliptin group) were −0.011% in gemigliptin 25 mg bid and 0.004% in gemigliptin 50 mg qd.
Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [ 5 ] [ 6 ] It may have a role when thiazides , beta-blockers , ACE inhibitors , and calcium channel blockers are not appropriate or have failed to control blood pressure.